According to a new report, however, a competitor may be stealing the spotlight in 2025. GlobaData issued a report stating that it expects Eli Lilly’s Zepbound to lead the obesity market in the coming ...

INDIANAPOLIS (WISH) – The FDA has now approved Lilly’s Zepbound (glp-1 agonist) for sleep apnea. It’s the first medication approved for this condition. Sleep apnea affects 25 million ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

(NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward ...

(NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step forward for ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...